2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T73c,Antifungals are the standard treatment for onychomycosis. However, oral antifungals present contraindications and potential drug-drug interactions, while topical antifungals suffer from limited efficacy and penetration. Recently, researchers have explored physical therapies, including laser and photodynamic therapy. To evaluate the clinical efficacy of combining diode laser therapy with photodynamic therapy and ciclopirox 8% hydroxypropyl chitosan (HPCH) nail lacquer in treating onychomycosis. We conducted a randomised controlled clinical trial involving patients with onychomycosis. A total of 26 patients were enrolled and followed for 12 months. Participants received either eight sessions of laser treatment combined with three sessions of photodynamic therapy, or daily treatment with ciclopirox 8% HPCH. The clinical cure rate was 94.1% in the group treated with laser and photodynamic therapy, compared to 53.3% in the group treated with ciclopirox 8% HPCH (p = 0.008). All patients who achieved clinical cure with either treatment also reached mycologic and complete cure, with a rate of 100%. The average time to healing was significantly shorter for the group receiving laser and photodynamic therapy (3.6 ± 1.2 months) than for those treated with ciclopirox 8% HPCH nail lacquer (9.2 ± 1.6 months) (p < 0.001). In the laser and photodynamic therapy group, adverse events, specifically subungual hematoma and blisters, occurred in 11.4% of patients, with a recurrence rate of 33.3%. No adverse events or recurrence were observed in patients treated with ciclopirox 8% HPCH. Treatment of onychomycosis using diode laser and photodynamic therapy results in higher clinical cure rates and shorter healing times compared to the reference treatment with 8% ciclopirox HPCH. ClinicalTrials.gov identifier: NCT05809297.31:T9bb,ABSTRACTBackgroundAntifungals are the standard treatment for onychomycosis. However, oral antifungals present contraindications and potential drug–drug interactions, while topical antifungals suffer from limited efficacy and penetration. Recently, researchers have explored physical therapies, including laser and photodynamic therapy.ObjectiveTo evaluate the clinical efficacy of combining diode laser therapy with photodynamic therapy and ciclopirox 8% hydroxypropyl chitosan (HPCH) nail lacquer in treating onychomycosis.MethodsWe conducted a randomised controlled clinical trial involving patients with onychomycosis. A total of 26 patients were enrolled and followed for 12 months. Participants received either eight sessions of laser treatment combined with three sessions of photodynamic therapy, or daily treatment with ciclopirox 8% HPCH.ResultsThe clinical cure rate was 94.1% in the group treated with laser and photodynamic therapy, compared to 53.3% in the group treated with ciclopirox 8% HPCH (p = 0.008). All patients who achieved clinical cure with either treatment also reached mycologic and complete cure, with a rate of 100%. The average time to healing was significantly shorter for the group receiving laser and photodynamic therapy (3.6 ± 1.2 months) than for those treated with ciclopirox 8% HPCH nail lacquer (9.2 ± 1.6 months) (p < 0.001). In the laser and photodynamic therapy group, adverse events, specifically subungual hematoma and blisters, occurred in 11.4% of patients, with a recurrence rate of 33.3%. No adverse events or recurrence were observed in patients treated with ciclopirox 8% HPCH.ConclusionsTreatment of onychomycosis using diode laser and photodynamic therapy results in higher clinical cure rates and shorter healing times compared to the reference treatment with 8% ciclopirox HPCH.Trial RegistrationClinicalTrials.gov identifier: NCT0580929732:T6ac,Diabetic ulcers are a significant healthcare challenge, capable of diminishing quality of life, lengthening hospitalisation stay, and incurring substantial costs for patients and healthcare systems. Erbium-doped yttrium-aluminum-garnet (Er-YAG) laser has been evolving as a prospective intervention for addressing wounds of various aetiologies. Despite this, the literature remains limited in appraising the effectiveness of laser therapy specifically in diabetic wounds. This study investigates the impact of employing a spatially modulated Er-YAG laser as a therapeutic approach for treating diabetic ulcers. In a single-arm study conducted from November 2017 to April 2023, patients with hard-to-heal ulcers were treated in a two-step approach of wound debridement using Er-YAG laser for ablation and biostimulation through deep tissue resonance using RecoSMA (Multiline laser system, LINLINE MS, Latvia) laser technology. Ulcers received weekly laser treatment, together with routine care until healing occurred and were then followed up to observe any recurrence. The primary outcome measure was wound closure; the secondary outcome measures were time to closure, and the number of laser treatments required. Data related to sociodemographic details, size and number of diabetic ulcers, and number of sessions related to laser treatment were collected using a predesigned, pretested questionnaire before initiating the treatment. A total of 59 patients attending the clinic during the study period with diabetic ulcers were included in the study. The mean wound surface area at baseline was 25.7cm Spatially modulated erbium YAG laser is effective as a therapeutic approach for treating diabetic ulcers.33:T934,Objective: Diabetic ulcers are a significant healthcare challenge, capable of diminishing quality of life, lengthening hospitalisation stay, and incurring substantial costs for patients and healthcare systems. Erbium-doped yttrium-aluminum-garnet (Er-YAG) laser has been evolving as a prospective intervention for addressing wounds of various aetiologies. Despite this, the literature remains limited in appraising the effectiveness of laser therapy specifically in diabetic wounds. This study investigates the impact of employing a spatially modulated Er-YAG laser as a therapeutic approach for treating diabetic ulcers. Method: In a single-arm study conducted from November 2017 to April 2023, patients with hard-to-heal ulcers were treated in a two-step approach of wound debridement using Er-YAG laser for ablation and biostimulation through deep tissue resonance using RecoSMA (Multiline laser system, LINLINE MS, Latvia) laser technology. Ulcers received weekly laser treatment, together with routine care until healing occurred and were then followed up to observe any recurrence. The primary outcome measure was wound closure; the secondary outcome measures were time to closure, and the number of laser treatments required. Data related to sociodemographic details, size and number of diabetic ulcers, and number of sessions related to laser treatment were collected using a predesigned, pretested questionnaire before initiating the treatment. Results: A total of 59 patients attending the clinic during the study period with diabetic ulcers were included in the study. The mean wound surface area at baseline was 25.7cm2 (median: 12cm2). The average number of sessions of laser treatment required was 4.41, ranging from 1–11. The size of the ulcer reduced with each session of laser treatment. The diabetic ulcers healed completely at the end of the treatment, indicating the effectiveness of the Er-YAG/RecoSMA two-step approach. Conclusion: Spatially modulated erbium YAG laser is effective as a therapeutic approach for treating diabetic ulcers. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Laser Therapy: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Laser Therapy (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Laser%20Therapy\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Laser Therapy\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Laser%20Therapy\"}]}}"}}]],["$","$L2f",null,{"title":"Laser Therapy: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Laser Therapy — concise summaries and practical next steps.","papers":[{"doi":"10.1001/jamadermatol.2026.0413","pmid":"42418191","title":"Melasma","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-07-08T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2026.0413","source_score":3,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-13T17:42:28.088Z","updated_at":"2026-07-13T17:42:28.088Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.0413","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0413","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0413","tag_type":"condition","value":"Melasma","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0413","tag_type":"generic","value":"tranexamic acid","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0413","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0413","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0413","tag_type":"modality","value":"Chemical Peel","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0413","tag_type":"modality","value":"Laser Therapy","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0413","tag_type":"modality","value":"Microneedling","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0413","tag_type":"modality","value":"Topical Depigmenting Agent","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0413","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0413","tag_type":"study_design","value":"Patient Education / Review","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0413","tag_type":"warning","value":"Level of evidence is assigned as 7 (expert opinion/patient education material) given the absence of study methodology or data.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0413","tag_type":"warning","value":"Study design label 'Patient Education / Review' is used as no standard research design applies.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0413","tag_type":"warning","value":"This is a JAMA Dermatology Patient Page (lay education article), not a primary research study or systematic review — no original data or statistical findings are reported.","value_numeric":null}],"summaries":{"what_studied":"This Patient Page covers the causes, symptoms, diagnosis, and treatment options for melasma, targeting a general and clinical audience.","key_result":"Melasma affects about 1 in 100 people, is most common in women of reproductive age, and is more prevalent in those of African, Asian, Hispanic, and Middle Eastern ancestry. Treatments (topical agents, oral tranexamic acid, procedures) can improve but not cure the condition, with improvement often taking several months.","limitations":"This is a patient education summary, not an original research study — no primary data, control groups, or outcome measures are reported.","practice_takeaway":"Counsel patients that daily broad-spectrum tinted sunscreen (SPF ≥30), topical lightening agents, and — for severe cases — oral tranexamic acid are the mainstays of management. Set clear expectations: melasma is chronic, improvement takes months, and procedures should be done by a board-certified dermatologist to minimize adverse effects."}},{"doi":"10.1111/srt.70322","pmid":"41519967","title":"RETRACTION: High‐Powered 675‐nm Laser: Safety and Efficacy in Clinical Evaluation and In Vitro Evidence for Different Skin Disorders","journal_title":"Skin Research and Technology","journal_issn":"0909-752X","published_at":"2026-01-11T00:00:00.000Z","url":"https://doi.org/10.1111/srt.70322","source_score":5,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-13","doi":"10.1111/srt.70322","days":"7","issn":"0909-752X","rank":"9","field":"Clinical Medicine","score":"5","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/srt.70322","title":"RETRACTION: High-Powered 675-nm Laser: Safety and Efficacy in Clinical Evaluation and In Vitro Evidence for Different Skin Disorders.","journal":"Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)","methods":"","results":"","abstract":"","keywords":[],"pubmed_id":"41519967","conclusions":"","publication_date":"2026-01-11T00:00:00"},"crossref":{"DOI":"10.1111/srt.70322","URL":"https://doi.org/10.1111/srt.70322","ISSN":["0909-752X","1600-0846"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/srt.70322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"1","score":1,"title":["RETRACTION: High‐Powered 675‐nm Laser: Safety and Efficacy in Clinical Evaluation and In Vitro Evidence for Different Skin Disorders"],"author":null,"issued":{"date-parts":[[2026,1]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":"32","archive":["Portico"],"created":{"date-time":"2026-01-11T04:03:06Z","timestamp":1768104186000,"date-parts":[[2026,1,11]]},"indexed":{"date-time":"2026-01-11T07:15:49Z","timestamp":1768115749639,"date-parts":[[2026,1,11]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000,"date-parts":[[2026,1,10]]},"delay-in-days":9,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/srt.70322"}},"subtitle":[],"assertion":[{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-01-10"}],"deposited":{"date-time":"2026-01-11T04:03:07Z","timestamp":1768104187000,"date-parts":[[2026,1,11]]},"issn-type":[{"type":"print","value":"0909-752X"},{"type":"electronic","value":"1600-0846"}],"published":{"date-parts":[[2026,1]]},"publisher":"Wiley","reference":null,"update-to":[{"DOI":"10.1111/srt.70019","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000,"date-parts":[[2026,1,10]]}}],"short-title":[],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/srt.70322"],"article-number":"e70322","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Skin Research and Technology"],"published-print":{"date-parts":[[2026,1]]},"reference-count":0,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,10]]},"references-count":0,"short-container-title":["Skin Research and Technology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/srt.70322","is_oa":true,"title":"RETRACTION: High‐Powered 675‐nm Laser: Safety and Efficacy in Clinical Evaluation and In Vitro Evidence for Different Skin Disorders","updated":"2026-01-15T02:17:35+00:00","published_date":"2026-01-01","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/srt.70322","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/srt.70322","url_for_landing_page":"https://doi.org/10.1111/srt.70322"}}},"created_at":"2026-01-18T22:40:12.285Z","updated_at":"2026-01-20T15:55:50.695Z","tags":[{"paper_doi":"10.1111/srt.70322","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/srt.70322","tag_type":"condition","value":"Skin Disorders","value_numeric":null},{"paper_doi":"10.1111/srt.70322","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/srt.70322","tag_type":"modality","value":"Laser Therapy","value_numeric":null},{"paper_doi":"10.1111/srt.70322","tag_type":"study_design","value":"Editorial","value_numeric":null},{"paper_doi":"10.1111/srt.70322","tag_type":"warning","value":"Study design classification is approximate because this is not a primary research study.","value_numeric":null},{"paper_doi":"10.1111/srt.70322","tag_type":"warning","value":"This item is a retraction notice; no study data, sample size, or outcomes are provided.","value_numeric":null}],"summaries":{"what_studied":"Retraction of a paper that evaluated a high‑powered 675‑nm laser for safety and efficacy in clinical and in vitro settings across different skin disorders.","practice_takeaway":"Treat the findings of the retracted laser paper as unreliable and avoid using it to guide clinical decisions."}},{"doi":"10.1111/jocd.70495","pmid":"41051055","title":"A New Hope for Melasma: Long‐Term Clearance With 755‐nm Picosecond Alexandrite Laser and Topical JAK Inhibition","journal_title":"Journal of Cosmetic Dermatology","journal_issn":"1473-2130","published_at":"2025-10-06T00:00:00.000Z","url":"https://doi.org/10.1111/jocd.70495","source_score":4,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-06","doi":"10.1111/jocd.70495","days":"7","issn":"1473-2130","rank":"6","field":"Clinical Medicine","score":"4","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/jocd.70495","title":"A New Hope for Melasma: Long-Term Clearance With 755-nm Picosecond Alexandrite Laser and Topical JAK Inhibition.","journal":"Journal of cosmetic dermatology","methods":"","results":"","abstract":"","keywords":[],"pubmed_id":"41051055","conclusions":"","publication_date":"2025-10-06T00:00:00"},"crossref":{"DOI":"10.1111/jocd.70495","URL":"https://doi.org/10.1111/jocd.70495","ISSN":["1473-2130","1473-2165"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jocd.70495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"10","score":1,"title":["A New Hope for Melasma: Long‐Term Clearance With 755‐nm Picosecond Alexandrite Laser and Topical JAK Inhibition"],"author":[{"given":"Ali","family":"Al‐Mamoori","sequence":"first","affiliation":[{"name":"Department of Dermatology Baghdad Teaching Hospital, Baghdad Medical City Baghdad Iraq"}]},{"given":"Sajjad Ghanim","family":"Al‐Badri","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Warith Al‐Anbiyaa Karbala Iraq"}]},{"given":"Ibrahim","family":"Khalil","sequence":"additional","affiliation":[{"name":"Dhaka Medical College and Hospital Dhaka Bangladesh"}]},{"given":"Wael","family":"Al‐Daraji","sequence":"additional","affiliation":[{"name":"Dermatology Department Ain Shams University Hospital Cairo Egypt"}]}],"issued":{"date-parts":[[2025,10]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":"24","archive":["Portico"],"created":{"date-time":"2025-10-06T11:35:59Z","timestamp":1759750559000,"date-parts":[[2025,10,6]]},"indexed":{"date-time":"2025-10-06T12:11:56Z","timestamp":1759752716529,"date-parts":[[2025,10,6]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000,"date-parts":[[2025,10,6]]},"delay-in-days":5,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/jocd.70495"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-08-12"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-29"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-10-06"}],"deposited":{"date-time":"2025-10-06T11:36:02Z","timestamp":1759750562000,"date-parts":[[2025,10,6]]},"issn-type":[{"type":"print","value":"1473-2130"},{"type":"electronic","value":"1473-2165"}],"published":{"date-parts":[[2025,10]]},"publisher":"Wiley","reference":[{"DOI":"10.1038/jid.2010.95","key":"e_1_2_1_12_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/phpp.12086","key":"e_1_2_1_12_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00403‐023‐02794‐0","key":"e_1_2_1_12_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/phpp.12783","key":"e_1_2_1_12_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3389/fimmu.2019.02847","key":"e_1_2_1_12_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/jocd.70495"],"article-number":"e70495","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Cosmetic Dermatology"],"published-print":{"date-parts":[[2025,10]]},"reference-count":5,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10,6]]},"references-count":5,"short-container-title":["J of Cosmetic Dermatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/jocd.70495","is_oa":true,"title":"A New Hope for Melasma: Long‐Term Clearance With 755‐nm Picosecond Alexandrite Laser and Topical JAK Inhibition","updated":"2025-10-11T00:07:04+00:00","published_date":"2025-10-01","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jocd.70495","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jocd.70495","url_for_landing_page":"https://doi.org/10.1111/jocd.70495"}}},"created_at":"2025-10-09T07:08:12.717Z","updated_at":"2025-10-13T07:32:37.233Z","tags":[{"paper_doi":"10.1111/jocd.70495","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/jocd.70495","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/jocd.70495","tag_type":"condition","value":"Melasma","value_numeric":null},{"paper_doi":"10.1111/jocd.70495","tag_type":"generic","value":"tofacitinib","value_numeric":null},{"paper_doi":"10.1111/jocd.70495","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/jocd.70495","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1111/jocd.70495","tag_type":"modality","value":"Laser Therapy","value_numeric":null},{"paper_doi":"10.1111/jocd.70495","tag_type":"modality","value":"Sunscreen","value_numeric":null},{"paper_doi":"10.1111/jocd.70495","tag_type":"sample_size","value":"n=1","value_numeric":1},{"paper_doi":"10.1111/jocd.70495","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1111/jocd.70495","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.1111/jocd.70495","tag_type":"warning","value":"Combined intervention (laser, topical tofacitinib, tinted sunscreen) limits attribution of effect.","value_numeric":null},{"paper_doi":"10.1111/jocd.70495","tag_type":"warning","value":"Protocol details (device settings, formulation) are specific to this case, which may limit generalizability.","value_numeric":null},{"paper_doi":"10.1111/jocd.70495","tag_type":"warning","value":"Single-patient case report with no control; findings are hypothesis‑generating only.","value_numeric":null}],"summaries":{"what_studied":"Single-patient case report of a 31-year-old Fitzpatrick IV woman with 4-year refractory malar melasma treated with one 755‑nm picosecond alexandrite laser session, then maintenance with topical tofacitinib 2% twice daily plus iron oxide–tinted sunscreen, followed for 9 months.","key_result":"Marked clearance with homogeneous tone after the single laser session, maintained for 9 months before gradual relapse; no adverse effects, post‑inflammatory hyperpigmentation, or rebound were reported.","limitations":"Single patient with no comparator; multimodal regimen prevents attribution of benefit to any single component; follow‑up durability assessed only to 9 months.","practice_takeaway":"In darker phototypes with refractory melasma, a single 755‑nm picosecond alexandrite laser session followed by topical JAK inhibition and visible‑light photoprotection may achieve months‑long clearance without PIH, but this remains preliminary and needs confirmation in controlled studies."}},{"doi":"10.1111/myc.70121","pmid":"41024682","title":"Diode Laser and Red‐Laser Photodynamic Therapy Versus Ciclopirox 8% HPCH Nail Lacquer for the Treatment of Onychomycosis: A Randomised Controlled Trial","journal_title":"Mycoses","journal_issn":"0933-7407","published_at":"2025-09-30T00:00:00.000Z","url":"https://doi.org/10.1111/myc.70121","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-05","doi":"10.1111/myc.70121","days":"7","issn":"0933-7407","rank":"9","field":"Clinical Medicine","score":"1","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/myc.70121","title":"Diode Laser and Red-Laser Photodynamic Therapy Versus Ciclopirox 8% HPCH Nail Lacquer for the Treatment of Onychomycosis: A Randomised Controlled Trial.","journal":"Mycoses","methods":"","results":"The clinical cure rate was 94.1% in the group treated with laser and photodynamic therapy, compared to 53.3% in the group treated with ciclopirox 8% HPCH (p = 0.008). All patients who achieved clinical cure with either treatment also reached mycologic and complete cure, with a rate of 100%. The average time to healing was significantly shorter for the group receiving laser and photodynamic therapy (3.6 ± 1.2 months) than for those treated with ciclopirox 8% HPCH nail lacquer (9.2 ± 1.6 months) (p < 0.001). In the laser and photodynamic therapy group, adverse events, specifically subungual hematoma and blisters, occurred in 11.4% of patients, with a recurrence rate of 33.3%. No adverse events or recurrence were observed in patients treated with ciclopirox 8% HPCH.","abstract":"$30","keywords":["ciclopirox","laser","onychomycosis","photodynamic therapy","toluidine","topical antifungal","treatment"],"pubmed_id":"41024682","conclusions":"","publication_date":"2025-09-30T00:00:00"},"crossref":{"DOI":"10.1111/myc.70121","URL":"https://doi.org/10.1111/myc.70121","ISSN":["0933-7407","1439-0507"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/myc.70121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"10","score":1,"title":["Diode Laser and Red‐Laser Photodynamic Therapy Versus Ciclopirox 8% HPCH Nail Lacquer for the Treatment of Onychomycosis: A Randomised Controlled Trial"],"author":[{"given":"Sara","family":"García‐Oreja","sequence":"first","affiliation":[{"name":"University Podiatry Clinic, Faculty of Nursing, Physiotherapy and Podiatry Complutense University of Madrid Madrid Spain"}]},{"given":"Francisco Javier","family":"Álvaro‐Afonso","sequence":"additional","affiliation":[{"name":"Diabetic Foot Unit, University Podiatry Clinic, Faculty of Nursing, Physiotherapy and Podiatry, Complutense University of Madrid Health Research Institute of the San Carlos Clinical Hospital (IdISSC) Madrid Spain"}]},{"given":"David","family":"Navarro‐Pérez","sequence":"additional","affiliation":[{"name":"University Podiatry Clinic, Faculty of Nursing, Physiotherapy and Podiatry Complutense University of Madrid Madrid Spain"}]},{"given":"Diego","family":"León‐Herce","sequence":"additional","affiliation":[{"name":"University Podiatry Clinic, Faculty of Nursing, Physiotherapy and Podiatry Complutense University of Madrid Madrid Spain"}]},{"given":"Aroa","family":"Tardáguila‐García","sequence":"additional","affiliation":[{"name":"Diabetic Foot Unit, University Podiatry Clinic, Faculty of Nursing, Physiotherapy and Podiatry, Complutense University of Madrid Health Research Institute of the San Carlos Clinical Hospital (IdISSC) Madrid Spain"}]},{"given":"José Luis","family":"Lázaro‐Martínez","sequence":"additional","affiliation":[{"name":"Diabetic Foot Unit, University Podiatry Clinic, Faculty of Nursing, Physiotherapy and Podiatry, Complutense University of Madrid Health Research Institute of the San Carlos Clinical Hospital (IdISSC) Madrid Spain"}]}],"issued":{"date-parts":[[2025,9,30]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":"68","archive":["Portico"],"created":{"date-time":"2025-09-30T07:39:48Z","timestamp":1759217988000,"date-parts":[[2025,9,30]]},"indexed":{"date-time":"2025-10-01T15:53:38Z","timestamp":1759334018298,"date-parts":[[2025,10,1]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000,"date-parts":[[2025,9,30]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/myc.70121"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-07-23"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-18"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-09-30"}],"deposited":{"date-time":"2025-09-30T07:39:52Z","timestamp":1759217992000,"date-parts":[[2025,9,30]]},"issn-type":[{"type":"print","value":"0933-7407"},{"type":"electronic","value":"1439-0507"}],"published":{"date-parts":[[2025,9,30]]},"publisher":"Wiley","reference":[{"DOI":"10.1111/myc.13799","key":"e_1_2_11_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1159/000485632","key":"e_1_2_11_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/1203475417716362","key":"e_1_2_11_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/myc.13648","key":"e_1_2_11_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.16394","key":"e_1_2_11_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/myc.13683","key":"e_1_2_11_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.20986/revesppod.2024.1695/2024","key":"e_1_2_11_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/archdermatol.2011.267","key":"e_1_2_11_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/myc.13694","key":"e_1_2_11_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/myc.13543","key":"e_1_2_11_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/14651858.CD010031.pub2","key":"e_1_2_11_12_1","year":"2017","issue":"7","author":"Kreijkamp‐Kaspers S.","volume":"2017","first-page":null,"unstructured":null,"article-title":"Oral Antifungal Medication for Toenail Onychomycosis","journal-title":"Cochrane Database of Systematic Reviews","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_11_13_1","year":"2024","issue":"3","author":"Yousefian F.","volume":"17","first-page":"24","unstructured":null,"article-title":"Treatment Options for Onychomycosis: Efficacy, Side Effects, Adherence, Financial Considerations, and Ethics","journal-title":"Journal of Clinical and Aesthetic Dermatology","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_14_1","year":"2024","issue":"5","author":"Meretsky C. R.","volume":"16","first-page":null,"unstructured":null,"article-title":"Efficacy of Laser Therapy in Comparison With Other Methods for the Treatment of Onychomycosis: A Systematic Review and Meta‐Analysis","journal-title":"Cureus","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_15_1","year":"2020","issue":"1","author":"Foley K.","volume":"2020","first-page":null,"unstructured":null,"article-title":"Topical and Device‐Based Treatments for Fungal Infections of the Toenails","journal-title":"Cochrane Database of Systematic Reviews","doi-asserted-by":null},{"DOI":"10.3390/microbiolres16020051","key":"e_1_2_11_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.pdpdt.2025.104640","key":"e_1_2_11_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/jcm14051588","key":"e_1_2_11_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10103‐019‐02802‐8","key":"e_1_2_11_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10103-022-03561-9","key":"e_1_2_11_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/jof10110790","key":"e_1_2_11_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/jof8070742","key":"e_1_2_11_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Prospecto Ony‐Tec 80 mg/g Barniz De Uñas Medicamentoso ”https://cima.aemps.es/cima/dochtml/p/72143/P_72143.html?msclkid=2b172500c24f11ecad173503b80e7c56.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/ijd.16241","key":"e_1_2_11_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2023.2265658","key":"e_1_2_11_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1159/000488606","key":"e_1_2_11_26_1","year":"2018","issue":"1","author":"Piraccini B. M.","volume":"5","first-page":"13","unstructured":null,"article-title":"Ciclopirox Hydroxypropyl Chitosan: Efficacy in Mild‐To‐Moderate Onychomycosis","journal-title":"Skin Appendage Disorders","doi-asserted-by":"crossref"},{"DOI":"10.1007/s10103-017-2198-6","key":"e_1_2_11_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1155/2020/1216907","key":"e_1_2_11_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/myc.70121"],"article-number":"e70121","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Mycoses"],"published-print":{"date-parts":[[2025,10]]},"reference-count":27,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,9,30]]},"references-count":27,"short-container-title":["Mycoses"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/myc.70121","is_oa":true,"title":"Diode Laser and Red‐Laser Photodynamic Therapy Versus Ciclopirox 8% HPCH Nail Lacquer for the Treatment of Onychomycosis: A Randomised Controlled Trial","updated":"2025-10-03T07:17:10+00:00","published_date":"2025-09-30","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/myc.70121","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/myc.70121","url_for_landing_page":"https://doi.org/10.1111/myc.70121"}}},"created_at":"2025-10-08T07:09:18.220Z","updated_at":"2025-10-08T07:09:18.220Z","tags":[{"paper_doi":"10.1111/myc.70121","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"brand","value":"Ony-Tec","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"condition","value":"Onychomycosis","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"generic","value":"ciclopirox","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"modality","value":"Laser Therapy","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"modality","value":"Photodynamic Therapy","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"modality","value":"Topical Antifungal","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"sample_size","value":"n=26","value_numeric":26},{"paper_doi":"10.1111/myc.70121","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"warning","value":"Open‑label design and unequal visit frequency could bias adherence and assessments.","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"warning","value":"Outcomes were analyzed per nail; handling of patient‑level clustering was not described.","value_numeric":null},{"paper_doi":"10.1111/myc.70121","tag_type":"warning","value":"Time‑to‑healing values conflict between Table 2 and the text; the summary uses the values reported in the Results/Abstract.","value_numeric":null}],"summaries":{"what_studied":"A randomized, parallel-group trial of 26 adults with PCR/culture‑confirmed toenail onychomycosis compared eight sessions of diode laser (810/1064 nm) plus red‑laser photodynamic therapy (635 nm, toluidine blue) over 9 weeks versus daily ciclopirox 8% HPCH nail lacquer for at least 9 months, with 12‑month follow‑up.","key_result":"Clinical cure per nail was 94.1% with laser+PDT (16/17) vs 53.3% with ciclopirox (8/15) (p=0.008; OR 0.071, 95% CI 0.007–0.685); all clinically cured nails achieved mycologic and complete cure (100%). Time to healing was shorter with laser+PDT (3.6±1.2 vs 9.2±1.6 months; p<0.001); adverse events occurred in 11.4% of treated nails (all laser+PDT; subungual hematoma/blisters) and recurrences occurred in 6/24 cured nails (33.3% of laser+PDT patients), with none in the ciclopirox group.","limitations":"Small, single-center, open-label study with all procedures performed by one podiatrist. Microbiologic cultures were only repeated in clinically cured nails, which may overstate mycologic cure. Post‑treatment observation time and visit intensity differed between groups, potentially affecting recurrence and adherence.","practice_takeaway":"For adults who cannot take oral antifungals, an 8‑session diode laser plus red‑laser PDT protocol achieved higher clinical cure and faster healing than daily ciclopirox 8% HPCH, but with mild local adverse events and more recurrences in this small RCT. Consider selectively, pending confirmation in larger, blinded, multicenter trials."}},{"doi":"10.12968/jowc.2023.32.sup10a.s21","pmid":"37830841","title":"Spatially modulated erbium YAG laser as a treatment for diabetic ulcer","journal_title":"Journal of Wound Care","journal_issn":"0969-0700","published_at":"2023-10-13T00:00:00.000Z","url":"https://doi.org/10.12968/jowc.2023.32.sup10a.s21","source_score":151,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2023-10-29","doi":"10.12968/jowc.2023.32.sup10a.s21","days":"30","issn":"0969-0700","rank":"5","field":"Clinical Medicine","score":"151","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.12968/jowc.2023.32.Sup10a.S21","title":"Spatially modulated erbium YAG laser as a treatment for diabetic ulcer.","journal":"Journal of wound care","methods":"In a single-arm study conducted from November 2017 to April 2023, patients with hard-to-heal ulcers were treated in a two-step approach of wound debridement using Er-YAG laser for ablation and biostimulation through deep tissue resonance using RecoSMA (Multiline laser system, LINLINE MS, Latvia) laser technology. Ulcers received weekly laser treatment, together with routine care until healing occurred and were then followed up to observe any recurrence. The primary outcome measure was wound closure; the secondary outcome measures were time to closure, and the number of laser treatments required. Data related to sociodemographic details, size and number of diabetic ulcers, and number of sessions related to laser treatment were collected using a predesigned, pretested questionnaire before initiating the treatment.","results":"A total of 59 patients attending the clinic during the study period with diabetic ulcers were included in the study. The mean wound surface area at baseline was 25.7cm","abstract":"$32","keywords":["RecoSMA technology","diabetic foot ulcer","diabetic ulcer","diabetic wound","erbium YAG","hard-to-heal wounds","laser","wound","wound care","wound dressing","wound healing"],"pubmed_id":"37830841","conclusions":"Spatially modulated erbium YAG laser is effective as a therapeutic approach for treating diabetic ulcers.","publication_date":"2023-10-13T00:00:00"},"crossref":{"DOI":"10.12968/jowc.2023.32.sup10a.s21","URL":"https://doi.org/10.12968/jowc.2023.32.sup10a.s21","ISSN":["0969-0700","2052-2916"],"link":[{"URL":"http://www.magonlinelibrary.com/doi/pdf/10.12968/jowc.2023.32.Sup10a.S21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"S21-S29","type":"journal-article","issue":"Sup10a","score":1,"title":["Spatially modulated erbium YAG laser as a treatment for diabetic ulcer"],"author":[{"given":"Ram M","family":"Chilgar","sequence":"first","affiliation":[{"name":"Department of Plastic Surgery, Elrevo Clinic, Aurangabad, Maharashtra, India"},{"name":"Department of Community Medicine, Government Medical College Aurangabad, Maharashtra, India"}]},{"given":"Smita P","family":"Andurkar","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Government Medical College Aurangabad, Maharashtra, India"}]}],"issued":{"date-parts":[[2023,10,1]]},"member":"5130","prefix":"10.12968","source":"Crossref","volume":"32","created":{"date-time":"2023-10-13T12:56:43Z","timestamp":1697201803000,"date-parts":[[2023,10,13]]},"indexed":{"date-time":"2025-08-02T05:05:40Z","timestamp":1754111140403,"date-parts":[[2025,8,2]]},"subject":[],"abstract":"$33","language":"en","relation":{},"resource":{"primary":{"URL":"http://www.magonlinelibrary.com/doi/10.12968/jowc.2023.32.Sup10a.S21"}},"subtitle":[],"deposited":{"date-time":"2023-10-13T12:56:53Z","timestamp":1697201813000,"date-parts":[[2023,10,13]]},"issn-type":[{"type":"print","value":"0969-0700"},{"type":"electronic","value":"2052-2916"}],"published":{"date-parts":[[2023,10,1]]},"publisher":"Mark Allen Group","reference":[{"DOI":"10.1016/j.jdiacomp.2022.108390","key":"B1","year":"2023","issue":"2","author":"Liarakos AL","volume":"37","first-page":"108390","unstructured":null,"article-title":null,"journal-title":"J Diabetes Complications","doi-asserted-by":"crossref"},{"DOI":"10.1007/s13300-012-0004-9","key":"B2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"B3","year":"2022","issue":"4","author":"Bereda G.","volume":"15","first-page":null,"unstructured":null,"article-title":null,"journal-title":"Curr Res Diabetes Obes J","doi-asserted-by":null},{"DOI":"10.1016/j.foot.2006.05.004","key":"B4","year":"2006","issue":"4","author":"Kazemi-Khoo N.","volume":"16","first-page":"184","unstructured":null,"article-title":null,"journal-title":"Foot","doi-asserted-by":"crossref"},{"DOI":"10.2165/00128071-200304010-00001","key":"B5","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/PRS.0b013e318186ccf2","key":"B6","year":"2008","issue":"5","author":"Mezzana P","volume":"122","first-page":"164e","unstructured":null,"article-title":null,"journal-title":"Plast Reconstr Surg","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0733-8635(05)70286-2","key":"B7","year":"2001","issue":"3","author":"Alster TS","volume":"19","first-page":"453","unstructured":null,"article-title":null,"journal-title":"Dermatol Clin","doi-asserted-by":"crossref"},{"DOI":"10.5978/islsm.17-OR-17","key":"B8","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2337/diacare.17.9.1050","key":"B9","year":"1994","issue":"9","author":"Del Aguila MA","volume":"17","first-page":"1050","unstructured":null,"article-title":null,"journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.4103/ijo.IJO_1627_21","key":"B10","year":"2021","issue":"11","author":"Mohan V","volume":"69","first-page":"2932","unstructured":null,"article-title":null,"journal-title":"Indian J Ophthalmol","doi-asserted-by":"crossref"},{"DOI":null,"key":"B11","year":"2020","issue":"6","author":"Das A","volume":"12","first-page":"e8636","unstructured":null,"article-title":null,"journal-title":"Cureus","doi-asserted-by":null},{"DOI":"10.1111/iwj.12187","key":"B12","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"B13","year":"2015","issue":"3","author":"Hernández E","volume":"41","first-page":"271","unstructured":null,"article-title":null,"journal-title":"Ibero-Latin American Plastic Surgery","doi-asserted-by":null},{"DOI":null,"key":"B14","year":"16","issue":null,"author":"Rafetto JD.","volume":"31","first-page":"68","unstructured":null,"article-title":null,"journal-title":"Phebology","doi-asserted-by":null},{"DOI":"10.1016/S0741-5214(02)75295-6","key":"B15","year":"2003","issue":"6","author":"Lal BK","volume":"37","first-page":"1285","unstructured":null,"article-title":null,"journal-title":"J Vasc Surg","doi-asserted-by":"crossref"},{"DOI":"10.1111/wrr.12764","key":"B16","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1089/photob.2019.4646","key":"B17","year":"2019","issue":"9","author":"Trelles MA","volume":"37","first-page":"515","unstructured":null,"article-title":null,"journal-title":"Photobiomodulation, Photomedicine, and Laser Surgery","doi-asserted-by":"crossref"},{"DOI":"10.18484/2305-0047.2015.2.131","key":"B18","year":"2015","issue":"2","author":"Pikirenia II","volume":"23","first-page":"131","unstructured":null,"article-title":null,"journal-title":"Novosti Khirurgii","doi-asserted-by":"crossref"},{"DOI":"10.12968/jowc.2016.25.Sup6.S1","key":"B19","year":"2016","issue":null,"author":"Franks PJ","volume":"25","first-page":null,"unstructured":null,"article-title":null,"journal-title":"J Wound Care","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"Sup10a","published-print":{"date-parts":[[2023,10,1]]}},"alternative-id":["10.12968/jowc.2023.32.Sup10a.S21"],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["Journal of Wound Care"],"published-print":{"date-parts":[[2023,10,1]]},"reference-count":19,"published-online":null,"references-count":19,"short-container-title":["J Wound Care"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.12968/jowc.2023.32.sup10a.s21","is_oa":false,"title":"Spatially modulated erbium YAG laser as a treatment for diabetic ulcer","updated":"2025-05-22T18:42:22+00:00","published_date":"2023-10-01","best_oa_location":null}},"created_at":"2025-09-20T18:31:07.946Z","updated_at":"2025-09-20T18:38:40.329Z","tags":[{"paper_doi":"10.12968/jowc.2023.32.sup10a.s21","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.12968/jowc.2023.32.sup10a.s21","tag_type":"condition","value":"Diabetic Ulcer","value_numeric":null},{"paper_doi":"10.12968/jowc.2023.32.sup10a.s21","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.12968/jowc.2023.32.sup10a.s21","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.12968/jowc.2023.32.sup10a.s21","tag_type":"modality","value":"Laser Therapy","value_numeric":null},{"paper_doi":"10.12968/jowc.2023.32.sup10a.s21","tag_type":"sample_size","value":"n=59","value_numeric":59},{"paper_doi":"10.12968/jowc.2023.32.sup10a.s21","tag_type":"study_design","value":"Case Series","value_numeric":null},{"paper_doi":"10.12968/jowc.2023.32.sup10a.s21","tag_type":"warning","value":"Abstract text appears truncated (baseline wound area value incomplete).","value_numeric":null},{"paper_doi":"10.12968/jowc.2023.32.sup10a.s21","tag_type":"warning","value":"Outcome data are not provided in the abstract excerpt, so effectiveness cannot be quantified.","value_numeric":null},{"paper_doi":"10.12968/jowc.2023.32.sup10a.s21","tag_type":"warning","value":"The design is labeled here as a case series based on a single-arm description; classification may be approximate.","value_numeric":null}],"summaries":{"what_studied":"Single-arm study (Nov 2017–Apr 2023) of patients with diabetic ulcers treated weekly using a two-step Er:YAG laser protocol (ablation debridement plus RecoSMA biostimulation) alongside routine care, with primary outcome of wound closure and secondary outcomes of time to closure and number of treatments; N=59.","limitations":"Single-arm design without a comparator; no numerical outcomes (closure rates, times, or sessions) are reported in the provided text; follow-up details for recurrence are not specified."}}],"initialOffset":5,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Laser Therapy"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Laser Therapy"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Laser Therapy"}}}]]

Papers